메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

피죤, CIIE 2025서 '둥지' 주제로 혁신적 수유•유아 돌봄 과학 공개

[ 메디채널 김갑성 기자 ] 상하이 2025년 11월 8일 -- 고품질•정밀 설계된 유아 및 임산부용 제품 분야에서 신뢰받는 글로벌 선도기업 피죤(Pigeon)이 상하이 국가전시컨벤션센터(National Exhibition and Convention Center)에서 열린 제8회 중국국제수입박람회(China International Import Expo•CIIE)에서 '둥지(The Nest)'라는 주제로 수유 및 유아 돌봄 과학 분야의 최신 성과를 선보였다. 중국 진출 23년 맞은 피죤, 현지 혁신에서 글로벌 리더십으로 확장 CIIE 소비재 전시관(6.1관)에서 피죤의 아기 젖병은 관람객들로부터 큰 주목을 받았다. 저우지안펑(Zhou Jianfeng) 피죤 차이나 사장은 올해 중국 진출 23년을 맞이한 피죤이 그동안 걸어온 길에 대해 이렇게 말했다. "피죤은 일본에서 직접 제품을 가져오면서 중국에서의 여정을 시작했다. 시간이 흐르면서 중국 내에서 제조 시설 3곳과 연구개발(R&D) 센터를 1곳을 구축하고, 첨단 기술과 품질 시스템을 도입해 현지 가정에 신뢰할 수 있는 솔루션을 제공하기
- 김갑성 기자
- 2025-11-08 21:34
Xinhua Silk Road: E. China's Weihai City establishes 18 TCM h…

BEIJING, Nov. 8, 2025 -- Weihai, a prefecture-level city in east China's Shandong Province, has seen the establishment of 18 traditional Chinese medicine (TCM) health tourism demonstration bases, including the Weihai Tianmu Hot Spring Resort, as the city has emphasized the deep integration of tourism with TCM and health and wellness in recent years. The forest coverage here is high and the environment is beautiful, said a tourist from Qingdao who was on a tour with her friends in the Weihai Tianmu Hot Spring Resort, adding that she and her friends had experienced the hot spring here wh
- 김갑성 기자
- 2025-11-08 20:48
SanegeneBio Announces RNAi Licensing and Research C…

[ 메디채널 김갑성 기자 ] -Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("Lilly"). The companies will collaborate to advance RNAi candidates for metabolic diseases, based on SanegeneBio's proprietary tissue selective delivery technology, LEAD™ (Ligand and Enhancer Assisted Delivery). SanegeneBio will be responsible for discovery and identificatio
- 김갑성 기자
- 2025-11-08 18:00
inne Debuts at CIIE with Global Launch of Two New Products

SHANGHAI, Nov. 8, 2025 -- The 8th China International Import Expo (CIIE) commenced on Nov. 5 in Shanghai, China. The world's leading children's nutrition brand inne® was invited to participate, showcasing a range of its innovative achievements on this international stage and seizing the opportunity to share in China's development alongside global enterprises. Under the exhibition theme "Scientific Nutrition for a Shared Healthy Future," inne® unveiled the "Children's Calcium Quality Standard" on-site and globally launched two new products: inne® Women's
- 김갑성 기자
- 2025-11-08 11:23
Get Ready for the Holidays as VARON Launches Black Friday E…

NEW YORK, Nov. 7, 2025 -- As the holiday season approaches, one essential product that continues to improve lives is the oxygen concentrator. For individuals living with chronic respiratory conditions, having reliable access to supplemental oxygen can make a world of difference—enhancing comfort, mobility, and confidence in daily life. Just ahead of Black Friday, VARON, a trusted provider of portable oxygen concentrators and home oxygen concentrator machines, has launched its Black Friday Early Access Sale—offering a 20% sitewide discount and up to 40% off featur
- 김갑성 기자
- 2025-11-07 23:31
Lunit AI Maps the Tumor-Immune Landscape to Predict Immu…

Studies reveal how the Lunit SCOPE® suite identifies immunotherapy-responsive subtypes, standardizes immune phenotyping, and accelerates antibody-based target discovery SEOUL, South Korea, Nov. 7, 2025 -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting, taking place November 5-9 in Maryland, U.S. The findings highlight how Lunit's AI-powered digital pathology technologies—Lunit SCOPE IO® and Lunit SCOPE®
- 김갑성 기자
- 2025-11-07 22:05
HanchorBio Presents Two Late-Breaking Abstracts at the So…

[ 메디채널 김갑성 기자 ] Late-breaking poster presentations show HCB101's favorable safety, strong receptor occupancy, and promising monotherapy and combination activity in tumors historically unresponsive to immunotherapy TAIPEI, SHANGHAI, and SAN FRANCISCO, Nov. 7, 2025 -- HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced the presentation of two late-breaking abstracts on its lead asset, HCB101, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- 김갑성 기자
- 2025-11-07 22:00
2025 Aurora Prize for Awakening Humanity Awarded to Dr. Jamal E…

Head of Al Nao Hospital in Sudan recognized for sustaining critical medical care amid civil warand saving hundreds of lives NEW YORK, Nov. 7, 2025 -- The Aurora Humanitarian Initiative announced Thursday evening that Dr. Jamal Eltaeb has been named the 2025 Aurora Prize Laureate. The $1 million Aurora Prize for Awakening Humanity honors individuals who risk their lives to save others. This year, Aurora recognizes Dr. Eltaeb's extraordinary courage and steadfast dedication to providing care for those trapped in conflict. Amid Sudan's devastating civil war and the
- 김갑성 기자
- 2025-11-07 21:59
Brii Biosciences Announces Publication of Phase 2 ENSURE S…

Findings provide scientific insights into the contribution of small interfering RNA (siRNA) and therapeutic vaccination towards the HBV functional cure strategy DURHAM, N.C. and BEIJING, Nov. 7, 2025 -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today announced the publication of results from its Phase 2 ENSURE study in the peer-reviewed journal Nature Medicine. The study evaluates the efficacy and safet
- 김갑성 기자
- 2025-11-07 21:30
EBR Systems Achieves First Enrollments in the WiSE-UP Study for H…

The WiSE-UP post-approval study is gathering real-world evidence from commercially treated patients using the WiSE® left ventricular endocardial pacing (LVEP) system. Key Highlights: The first two patients have now been enrolled in the WiSE-UP post-approval study by Dr Devi Nair from St Bernards Heart & Vascular Center, Arkansas The EBR-sponsored study will evaluate real-world outcomes for heart failure patients receiving the FDA-approved WiSE® System for delivering LVEP in patients unable to receive traditional cardiac resynchronization therapy (CRT) T
- 김갑성 기자
- 2025-11-07 21:00

이전

1 2 3 4 5 6 7 8 9 10

많이 본 기사

최근기사

2025-11-09_SUN

2025-11-08_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 11월 09일 08시 40분